BMO Capital Maintains Market Perform on Fate Therapeutics, Lowers Price Target to $5.4
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Etzer Darout has maintained a 'Market Perform' rating on Fate Therapeutics (NASDAQ:FATE) but lowered the price target from $6 to $5.4.
August 09, 2023 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital has maintained its 'Market Perform' rating on Fate Therapeutics but lowered the price target from $6 to $5.4.
The lowering of the price target by BMO Capital indicates a less optimistic outlook for the stock, which could potentially lead to a decrease in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100